Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q2 2023 Earnings Presentation
14 slides from Bioarctic Ab Class B's earnings presentation, Jul 12, 2023
Slide 1: Q2 Report April-June 2023
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Q2 Report April-June 2023 Stockholm, July 12, 2023 Gunilla Osswald, PhD, CEO Anders Martin-Löf, CFO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: LEQEMBI (lecanemab) approved in the US – the world's first fully approved disease-modifying treatment for AD
LEQEMBI® (lecanemab) approved in the US – the world’s first fully approved disease-modifying treatment for AD • On June 9, the FDA Advisory Committee voted unanimously confirming the clinical benefit of LEQEMBI • On July 6, the FDA granted Eisai traditional approval for LEQEMBI for the treatment of
Slide 4: Lecanemab has the potential to become the first anti-Aβ antibody to receive full approval globally
Lecanemab has the potential to become the first anti-Aβ antibody to receive full approval globally USA Japan EU China Rest of World Canada: Submission FDA granted Leqembi Marketing authorization Marketing authorization Initiated Biologics accepted May 14, 2023 traditional approval application submit
Slide 5: Global estimates for future early AD patients treated with DMTs offer substantial room for growth
Global estimates for future early AD patients treated with disease modifying treatments (DMTs) offer substantial room for growth Eisai estimate 2032: ~240 million Prevalence Early AD Opportunities that could increase patient access: Presents to • Patient awareness and less stigma healthcare • Educat
Slide 6: Partnership model to de-risk clinical development and optimize commercialization opportunity
Partnership model to de-risk clinical development and optimize commercialization opportunity Alzheimer’s disease Partner track record Discovered and developed world’s best-selling medicine Used to treat confusion for symptoms in Alzheimer’s (dementia) related to disease Alzheimer's disease Industry-
Slide 7: Attractive and well-balanced project portfolio
Attractive and well-balanced project portfolio Regulatory Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 & Market ALZHEIMER’S DSEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease2 Lecanemab (BAN2401) (AHEAD 3-45) Eisai1 Preclinical (asymptomatic) Alzheimer’s diseas
Slide 8: Financial Summary
Financial Summary 8 BioArctic AB
Slide 9: Operating expenses 2023 within guidance
Operating expenses 2023 within guidance Net Revenues (SEK M) OPEX by item (SEK M) Operating Profit/Loss (SEK M) 120 104 301 393 96 100 86 80 132 61 218 60 45 48 50 42 40 20 -37 -39 -44 -46 -60 4 5 4 4 2 3 -101 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 2022 2023 2
Slide 10: Strong financial position
Strong financial position Cash Balance (SEK M) Cash Flow From Operating Net Result (SEK M) Activities (SEK M) 299 294 1 106 1 042 892 863 137 848 801 805 752 112 -38 -19 -44 -46 -58 -102 -35 -39 -40 -46 -58 -64 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 2022 2023 20
Slide 11: Upcoming news flow and closing remarks
Upcoming news flow and closing remarks 11 BioArctic AB
Slide 12: Upcoming news flow
Upcoming news flow Q3 2023 Q4 2023 Q1 2024 Congresses AAIC, Jul 16-20 CTAD, Oct 24-27 AD/PD Mar 5-9 Lecanemab Lecanemab U.S. PDUFA & CMS s.c. and maintenance Jul 6 dosing U.S. regulatory filing Lecanemab Japan Lecanemab EU & regulatory response China regulatory response PDUFA – Prescription Drug Use
Slide 13: BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients
” BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients with neurodegenerative diseases. 13 BioArctic AB
Slide 14: IR team
IR team GUNILLA OSSWALD, CEO ANDERS MARTIN-LÖF, OSKAR BOSSON, VP CECILIA LANNEBO, CFO COMMUNICATIONS & IR DIRECTOR IR To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com Contact: Next Report: Oskar Bosson, Q3 Report VP Communications & IR Jul-Sep